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CXCR7 is an atypical receptor for the chemokines CXCL11 and
CXCL12, which were found to be involved in animal models
of allograft injury. We studied the expression of CXCR7 and
its ligands in human kidneys by first quantifying the mRNA in
53 renal allograft biopsies. Receptor and ligand mRNAs were
expressed in renal allografts, with a significant induction of
CXCL11 and CXCL12 in biopsies showing borderline lesions
and acute rejection. Immunohistochemical analysis for CXCR7
was performed in a series of 64 indication and 24 protocol
biopsies. The indication biopsies included 46 acute rejections,
6 with interstitial fibrosis and tubular atrophy, and 12
pretransplant biopsies as controls. In control biopsies, CXCR7
protein was found on smooth muscle and on endothelial
cells of a small number of peritubular vessels. The number
of CXCR7-positive vessels was increased in acute rejection
and, using double immunofluorescence labeling, a subset
of these CXCR7-positive endothelial cells were identified as
lymphatic vessels. Both CXCR7-positive blood and lymphatic
vessels increased during allograft rejection. We found that
CXCR7 is present in both blood and lymphatic endothelial
cells in human renal allografts. Whether its presence
modulates the formation of chemokine gradients and the
recruitment of inflammatory cells will require further
experimental studies.
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Recruitment of inflammatory cells has a major function for
allograft survival in almost all forms of renal allograft injury
ranging from ischemia reperfusion, acute allograft rejection
to chronic injury (interstitial fibrosis and tubular atrophy).1,2
Chemokines are members of a large family of chemotactic
cytokines, which are involved in organogenesis, organization
of the immune system, the formation of lymphoid tissue,
leukocyte recirculation, and the recruitment of inflammatory
cells to vascularized allografts.2–5
CXCR7 is a recently de-orphanized receptor (also known
as RDC1). It was first cloned according to its homology with
the conserved domain of G-protein-coupled receptors.6
Binding of radiolabeled CXCL12 to embryonic liver cells
from CXCR4-deficient mice led to the description of a second
receptor for CXCL12.7–9 CXCR7 also binds CXCL11 with
high affinity.7–9
CXCR7 is an ‘atypical’ chemokine receptor as binding of
chemokines does not result in mobilization of intracellular
calcium, nor does it provoke direct chemotaxis of CXCR7-
positive cells.9,10 Conversely, CXCR7 is involved in various
biologic processes including tumor formation,8,11 transen-
dothelial migration of tumor cells,12 modulation of CXCL12-
induced migration,9 internalization of the ligand after
chemokine exposure,9 angiogenesis,13 and recruitment of
renal stem cells.14
At the moment relatively little is known about the
expression of CXCR7 in human tissues. CXCR7 was des-
cribed on normal as well as neoplastic endothelial cells,8,15,16
and proliferation of these cells was prevented by antisense
molecules to CXCR7.17 There has been some controversy on
the expression of CXCR7 on inflammatory cells, such as
monocytes, B cells, and dendritic cells.18,19 Chemotaxis of
T cells toward CXCL12 was blocked by an anti-CXCR7
antibody, whereas other groups did not reproduce these
results.8,9 In gene chip analysis of human immune cells, the
expression of CXCR7 was shown on B cells, some T-cell
subsets, and NK cells, but there was only a marginal effect of
CXCR7 deficiency on B-cell development in mice.20
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CXCR7 is an interesting molecule for allograft injury, as
both of its ligands were found to be of functional importance
in allograft models, and are present in human allograft
tissue.21–25 As an essential prerequisite for studies on the
functional role of CXCR7, we evaluated the expression of
CXCR7 and localized it in human renal allografts.
RESULTS
Expression of CXCR7, CXCL11, and CXCL12 mRNA in renal
allograft biopsies
The mRNA expression of CXCR7 and the corresponding
ligands was studied in microdissected tissues from allograft
biopsies of patients with borderline lesions (n¼ 12), acute
rejection (n¼ 23; Banff I, 10; Banff II, 13), signs of chronic
injury (n¼ 10), and biopsies taken before implantation from
living donors (n¼ 8) as controls (Figure 1, Table 1). All three
genes were found to be expressed in the tubulointerstitium of
renal allografts (Figure 1). CXCL11 mRNA showed the
strongest expression, significantly increased during acute
rejection, and was significantly lower in patients with signs of
chronic injury (as compared to acute rejection, Figure 1a).
CXCL12 mRNA was also found to be induced during acute
allograft rejection (Figure 1b). Interestingly, both chemokines
were significantly increased in biopsies with borderline
lesions, with no difference between biopsies with borderline
lesions and biopsies with acute rejection (Figure 1a and b).
CXCR7 mRNA was detected in all biopsies but showed no
change of expression levels in rejection or chronic injury
(Figure 1c). A positive correlation was found between the
expression of CXCL12 and the expression of CXCR7
(Spearman r¼ 0.53, Po0.0001), but not with the expression
of CXCL11 (not significant). There was no correlation bet-
ween CXCR7, CXCL12, CXCL11, and serum-creatinine or
proteinuria at the time of biopsy. CXCR7 was not consis-
tently detected by real-time RT-PCR (40 cycles) in isolated
glomeruli of the same patient cohort.
Localization of CXCR7 in well-preserved renal tissue from
tumor nephrectomies and pretransplant biopsies
Immunohistochemistry for CXCR7 was performed in well-
preserved renal tissue reflected by 12 biopsies from allografts
taken before implantation and the normal area of a tumor
nephrectomy specimen (Figure 2). In these well-preserved
kidneys, three sites of CXCR7 protein expression were identi-
fied, that is, endothelial cells, smooth muscle cells of vessel
walls, and tubular epithelial cells (Figure 2a–c). The endo-
thelial cells of scattered peritubular capillaries were CXCR7
positive, but the overall number of CXCR7-positive vessels
was low (Figure 2a). Some larger veins showed CXCR7-
positive endothelial cells (Figure 2e). No CXCR7-positive
cells were found to be present in the normal glomerular tufts
(Figure 2b and d). The arterioles at the vascular pole stained
positive for CXCR7 (Figure 2d). Smooth muscle cells of
arterial walls showed a positive signal (Figure 2b and e).
Some tubular epithelial cells were positive on the basolateral
side (Figure 2c). Morphologically, the CXCR7-positive
tubular segments were consistent with distal tubules and
collecting ducts.
Expression of CXCR7 in renal allografts
To describe the expression of CXCR7 in different forms of
renal allograft injury, we stained sections from allograft
nephrectomies due to terminal failure (Figure 3), as well as
renal allograft biopsies, including biopsies with acute rejection
(Banff I, n¼ 22; Banff II, n¼ 11; antibody mediated, n¼ 13)
and with chronic allograft injury (n¼ 6). The basic clinical
parameters were summarized in Table 2.
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Figure 1 |mRNA expression of CXCL11, CXCL12, and CXCR7 in
the tubulointerstitium. The mRNA expression was quantified by
real-time RT-PCR in renal allograft biopsies with borderline lesions
(borderline), acute rejection, signs of chronic injury (IF/TA), and from
living donors taken before implantation as controls (pre-Tx). (a and b)
A significant induction of CXCL11 (a) and CXCL12 (b) mRNAs was
present in biopsies with borderline lesions and with acute rejection.
(c) No change in CXCR7 mRNA expression was detectable.
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A prominent number of CXCR7-positive small vessels
in the tubulointerstitium was present in renal allografts
(Figure 3). This high number of CXCR7-positive interstitial
vessels was found in all forms of acute allograft rejection
(Figure 3e–h). CXCR7-positive vessels in the tubulointersti-
tium were associated with sites of inflammatory cell
accumulation (Figure 3a and h). It was common that
CXCR7-positive vessels were found within or in proximity
to sites of nodular infiltrates (Figure 3h). Morphologically,
two types of interstitial vessels were present. The first
resembled peritubular capillaries (Figure 3g). The second
type was present in proximity to arteries, but also in the rest
of the cortex with a slit-like appearance (Figure 3a and e).
Morphology and distribution of these vessels were consistent
with lymphatic vessels. Although the overall number of these
CXCR7-positive vessels was higher than in controls, there was
a high variability between biopsies with the same morpho-
logical diagnosis. Interestingly, the biopsies with acute
humoral rejection showed the lowest number of CXCR7-
positive vessels. There was no association with the depositon
of C4d. Furthermore, there was no association between the
number of CXCR7-positive vessels and serum-creatinine (at
the time of biopsy), or the number of globally sclerosed
glomeruli (indicating progressive injury).
Table 1 | Basic clinical data on the mRNA study population
(range)
Diagnosis n
Gender
(m/f)
Mean age
(years)
Time after
Tx (months)
Creatinine
(mg/dl)
Borderline 12 9/3 49 (25–66) 4.7 (0–24) 3.9 (1.5–10.4)
AR 23 17/6 52 (38–71) 3.3 (0–24) 5.7 (2–10.2)
IF/TA 10 NA 59 (42–71) 89 (12–180) 3.0 (1.4–6.2)
Pre-Tx 8 NA 50 (27–63) NA o1.1
Abbreviations: AR, acute rejection; f, female; IF/TA, interstitial fibrosis/tubular
atrophy; m, male; NA, not available; Pre-Tx, biopsy taken before implantation of the
allograft; Tx, transplantation.
Figure 2 | Expression of CXCR7 in controls.
Immunohistochemistry was performed on sections from tumor
nephrectomies (a, b) and pretransplant biopsies (c–e) with a
monoclonal antibody against CXCR7 (original magnification
 200). Expression of CXCR7 was detected on endothelial cells
(a, d, e, arrows), on smooth muscle cells of arteries (b, arrow), and
the basal aspect of tubular epithelial cells (c, arrow). Please note
the low number of peritubular capillaries positive for CXCR7 (a).
Figure 3 |CXCR7 expression in allograft nephrectomies and renal
biopsies with acute allograft rejection. Immunohistochemistry was
performed on sections of allograft nephrectomies (a–d) or allograft
biopsies with acute interstitial rejection (Banff I, e), acute vascular
rejection (Banff II, f), and acute antibody-mediated rejection (g, h)
with a monoclonal antibody against CXCR7 (original magnification
 200 a–d, g;  250 e;  100 f–h). A prominent number of CXCR7-
positive vessels (a, arrow) were present in the tubulointerstitium.
Glomerular capillaries were only occasionally CXCR7 positive (ranging
from single capillary loops (c, arrow) to the whole glomerular tuft (d)
being positive for CXCR7).
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Glomerular expression of CXCR7 on capillaries of the tuft
was found in allografts, but not in normal tissue (Figures 2,
3c and d). Expression on the endothelium of the glomerular
tuft was variable and ranged from a low number of
glomerular capillary loops (segmental expression) to CXCR7
expression on the majority of glomerular capillaries (Figure
3c and d). Although the expression of CXCR7 was most
prominent on glomeruli with signs of chronic allograft
glomerulopathy, it was not regularly associated with this
condition. In the allograft nephrectomy and transplant
biopsies, the CXCR7 expression on smooth muscle cells
and tubular epithelial cells was present as described for the
normal controls (Figure 3a).
Expression of CXCR7 on protocol biopsies
To confirm the results in an independent group of biopsies,
we performed immunohistochemistry for CXCR7 on an
additional series of 24 protocol biopsies. These biopsies
showed no signs of rejection (n¼ 12), acute rejection
(borderline, n¼ 4; Banff I, n¼ 2; Banff II, n¼ 1), or chronic
lesions with interstitial fibrosis and tubular atrophy (n¼ 5).
In the group with chronic lesions, two patients additionally
showed borderline lesions. The clinical data are presented
in Table 3. The vast majority of protocol biopsies were
performed at 3–4 months after transplantation.
The distribution of CXCR7 mirrored the pattern in
controls and indication biopsies. In the 12 biopsies without
signs of rejection, the number of CXCR7-positive vessels was
low (Figure 4a). A higher number of positive vessels was
present in protocol biopsies that showed acute rejections
(Figure 4a, Po0.05). The number of CXCR7-positive vessels
in patients with chronic lesions was higher than in controls,
but the difference did not quite reach the level of significance
(Figure 4a). The expression of CXCR7 on smooth muscle
cells of arteries and in some tubular epithelial cells did not
differ from the other morphological entities. The number of
CXCR7-positive vessels was not associated with the number
of globally sclerosed glomeruli. The serum-creatinine at the
time of biopsy correlated with the number of CXCR7-
positive interstitial vessels in this population (Figure 4b).
Expression of CXCR7 on lymphatic endothelium
The localization of CXCR7-positive small vessels close to
larger arteries, with a ‘slit’ appearance, indicated that these
might be lymphatic vessels. Therefore, we performed multi-
color immunofluorescence for podoplanin (a marker of
lymphatic vessels) and CXCR7 (Figures 5 and 6). In the
tubulointerstitium, CXCR7-positive vessels were present,
which were also positive for podoplanin (Figure 5). An addi-
tional population of CXCR7-positive small vessels was podo-
planin negative (that is, blood vessels). Both types expressed
the endothelial cell marker CD34 (not shown).
The number of single- and double-positive vessels was
quantified per high power field (Figure 6). In pretransplant
biopsies a low number of CXCR7-positive vessels was present
(Figure 6), with nine times more CXCR7-positive vessels than
Table 2 | Basic clinical data on the immunohistochemistry
study population (range)
Diagnosis n
Gender
(m/f)
Mean age
(years)
Time after
Tx (months)
Creatinine
(mg/dl)
Banff I 22 13/9 52 (27–71) 5.5 (0.2–28.3) 2.6 (0.9–5.2)
Banff II 11 4/7 53 (21–68) 0.9 (0.2–3.7) 4.3 (1.2–8.0)
AMR 13 8/5 44 (26–71) 4.8 (0.2–28.6) 4.6 (2.0–7.1)
IF/TA 6 5/1 59 (39–75) 82 (4.4–195) 2.5 (1.8–3.0)
Pre-Tx 12 6/6 50 (30–75) — NA
Abbreviations: AMR, antibody-mediated rejection; f, female; IF/TA, interstitial
fibrosis/tubular atrophy; m, male; NA, not available; Pre-Tx, biopsy taken before
implantation of the allograft; Tx, transplantation.
Table 3 | Basic clinical data on the protocol biopsies (range)
Diagnosis n
Gender
(m/f)
Mean age
(years)
Time after
Tx (months)
Creatinine
(mg/dl)
No R 12 8/4 48 (25–62) 3.8 (0.3–10) 1.5 (0.9–2)
AR 7 5/2 46 (35–67) 3.2 (0.2–6) 2.4 (1.2–3.3)*
IF/TA 5 4/1 49 (32–67) 3.5 (3–4) 1.9 (1.5–3)
Abbreviations: AR, acute rejection; f, female; IF/TA, interstitial fibrosis/tubular
atrophy; m, male; R, rejection; Tx, transplantation.
*Po0.05 vs no R.
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Figure 4 |Quantification of CXCR7 positive vessels in protocol
biopsies. (a) Illustrated are the mean numbers of CXCR7 positive
vessels per high power field (h.p.f.), in biopsies with no rejection
(no rej.), with acute rejection (acute rej.), and with signs of chronic
injury (IF/TA). The number of CXCR7 positive vessels was significantly
increased in biopsies with acute rejection. (b) A significant correlation
was documented between serum-creatinine and the number of
CXCR7 positive vessels.
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CXCR7-positive lymphatic vessels. In acute cellular rejection,
the number of CXCR7-positive vessels was significantly
higher (Banff I) as compared to biopsies taken before
implantation (Po0.05, Figure 6). The ratio between CXCR7-
positive vessels and lymphatic vessels was 3:1 (whereas it was
9:1 in normal tissue). This indicates an absolute increase in
CXCR7-positive lymphatic vessels. Two-third of the lympha-
tics were CXCR7 positive (whereas in normal tissue only one-
third of the lymphatics was CXCR7 positive).
In vascular rejection, the number of CXCR7-positive
vessels was also significantly higher compared to biopsies
taken before implantation (Po0.05, Figure 6). The ratio
of CXCR7-positive lymphatic vessels and blood vessels
remained similar to that seen in the biopsies taken before
implantation. Therefore, although the absolute numbers of
both vessel types increased, the main rise in CXCR7-positive
vessels was due to the single-positive peritubular capillaries
(blood vessel endothelium).
DISCUSSION
CXCR7 is a chemokine receptor that recently received a lot of
attention.7,11,12,14 It shares one ligand with the receptor
CXCR4 (CXCL12) and one with CXCR3 (CXCL11). Both of
these receptors were previously described in human renal
allografts, but were mainly found to be expressed by
infiltrating cells. In this study, we describe the expression of
CXCR7 on microvascular endothelial cells, with an induction
during acute allograft rejection in human renal allografts.
Also various functions of CXCR7, an atypical chemokine
receptor, have been recently described. Zabel et al.12 showed
that ligand binding to CXCR7 led to the recruitment of
b-arrestin2. Either CXCL11 or a small molecule CXCR7
ligand blocked transendothelial migration of tumor cells
(which were CXCR4 and CXCR7 positive).12 For renal stem
cells, it has also been shown that blocking either CXCR4 or
CXCR7 reduced the engraftment to injured kidneys and
transendothelial migration also required both receptors.14
Heterodimers form between CXCR7 and CXCR4, which
impairs CXCL12-mediated responses in primary lympho-
cytes.26 For these functions, CXCR7 and CXCR4 need to be
present on the same cell, which might be important for stem
cells, tumor cells, and inflammatory cells.
In line with our results, CXCR7 has also been shown to be
present on endothelial cells. Expression of CXCR7 was
induced by pro-inflammatory cytokines in human umbilical
vein endothelial cells in vitro.8 Hypoxia induced CXCR7 on
microvascular endothelial cells.27 Induction of CXCR7 was
also found on endothelial cells transformed by Kaposi’s
sarcoma-associated herpesvirus,15 and proliferation of these
cells was prevented by antisense molecules to CXCR7.17
Melanoma and malignant brain tumors were described
to contain CXCR7-positive vessels.16,27 The adhesion of
cells to human umbilical endothelial cells was increased
by endothelial CXCR7 expression.8 Therefore, CXCR7 is
expressed on a subset of blood endothelial cells, where it
is upregulated under inflammatory and hypoxic conditions.
This is consistent with our results of CXCR7 expression by
these cells in an inflammatory state such as acute renal
allograft rejection.
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Figure 5 | Localization of CXCR7 on lymphatic endothelium.
Multicolor immunofluorescence for CXCR7 (a, d, g) and lymphatic
endothelium (podoplanin, D2-40, b, e, h) was performed on tonsil
(a-c) or renal allograft nephrectomies (d-i, original magnification
 400). Nuclei are counterstained in blue (c, f, i). The overlay
is shown in c, f, i. The arrows localize double positive (CXCR7-
and podoplanin-positive lymphatic vessels), the arrowheads
show a CXCR7-positive vessel, which is podoplanin negative
(that is, a blood vessel).
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Figure 6 |Quantification of the multicolor immunofluorescence.
Multicolor fluorescence for CXCR7 and the lymphatic marker
podoplanin (D2-40) was performed and the positive vessels were
quantified (CXCR7, D2-40, and double positive). There was a
significant increase of CXCR7-positive vessels in biopsies with
acute rejection.
Kidney International (2010) 77, 801–808 805
MA Neusser et al.: CXCR7 in renal allografts o r ig ina l a r t i c l e
It might be important that in zebrafish the migration and
correct localization of CXCR4-positive primordial germ cells
was dependent on the expression of CXCR7-positive somatic
cells.28 CXCR7 knockdown resulted in misguidance of the
primordial germ cells.28,29 In this setting, the scavenging of
CXCL12 paves the way for new chemotactic gradients. The
function of endothelial CXCR7 in allografts remains to be
defined. It could increase adhesion (as shown for umbilical
vein endothelial cells), it could induce chemokine release (as
shown for CXCL8 in prostate carcinoma cells30), and it might
sharpen gradients. Whether CXCR7 might increase the
availability of CXCL11 and CXCL12 on the apical site of
endothelial cells (as it has been described for the Duffy
antigen/receptor for chemokines, another chemokine binding
protein) has not yet been shown.31
Lymphatic endothelial cells are a site of expression that
have not been shown previously. Studies on lymphatic vessels
and particularly their function in renal allografts are rapidly
evolving.32–34 The number of lymphatic vessels has been
shown to increase in renal allografts in association with sites
of inflammation and chronic injury.32,33 In other organs,
such as the transplanted heart, lymphatic vessels have been
shown to be of recipient origin.35 Accumulation of
inflammatory cells within these newly formed lymphatic
vessels might indicate a functional role in transplant
rejection.32–34 The impact of these vessels on allograft survival
is under intensive debate, with the current hypotheses
ranging from a potential positive to a detrimental effect. In
a study on renal allograft protocol biopsies, the graft function
at 1 year after transplantation was better when lymph vessels
were present at sites of inflammation compared to biopsies
without lymphatics in areas of cell recruitment.35 Here we
show the expression of CXCR7 on lymphatic endothelial cells
in renal allografts. The number of CXCR7-positive vessels
increased during acute interstitial allograft rejection. There-
fore CXCR7 is strategically situated at the site of inflamma-
tory cell efflux on lymphatics to modulate the chemokine
gradients at this site. The exit of inflammatory cells,
particularly dendritic cells, is regulated in part through
chemokines. Particularly the CCR7 ligand CCL21, and the
CXCR7 ligand CXCL12 have been shown to be involved in
lymphatic trafficking.36 The functional role on lymphatic
endothelial cells in renal allografts will undoubtedly be an
important question for future studies.
We found that both known ligands of CXCR7, that is,
CXCL11 and CXCL12, were significantly induced in human
renal allografts with acute allograft rejection. CXCL11 has
been previously localized in rat heart allografts to infiltrating
macrophages and endothelial cells.37 CXCL12 expression was
also found to be of functional importance in a rat kidney
transplantation model, as an anti-CXCL12 antibody delayed
signs of chronic rat allograft injury.21 The strong induction
of CXCL11 during acute rejection has been previously shown
by Panzer et al.38 Using in situ hybridization, a diffuse expression
of CXCL11 in the tubulointerstitium, most likely on endo-
thelial cells was demonstrated.38 CXCL11 has also been described
to be elevated in urine of patients with renal allografts.25
Interestingly, we found both chemokines to be significantly
upregulated in borderline lesions, with the level of expression not
significantly different to acute rejection. It was previously
thought that these chemokines function through the classical
receptors CXCR3 and CXCR4.38,39 We add a new receptor with
CXCR7, which might modulate the function of these chemo-
kines in renal allografts. In contrast to the increased number of
CXCR7-positive vessels by immunohistochemistry, we were
unable to detect an induction of CXCR7 mRNA. Differences
between mRNA expression data and localization of the protein
can be related to the absence of mRNA regulation, posttransla-
tional regulation differences.8 Furthermore, it would seem that
the induction of CXCR7 on endothelial cells represents a very
small number of cells within a large volume of the kidney. The
changes in the signal of CXCR7 mRNA in the vessels might not
be detectable due to the background noise of a variety of signals
from other cells in the tubulointerstitial space. Hence, although
the change on the vessels is significant, the change in the signal
for mRNA derived from the whole tubulointerstitial space might
not be detectable.
We were unable to show a direct correlation between renal
function and the number of CXCR7-positive vessels in
indication biopsies, but this association was significant in
protocol biopsies. Importantly, CXCR7-positive vessels were
also associated with sites of inflammatory cell accumulation.
From the increased expression of CXCR7 in association with
inflammatory cell accumulation, it might be hypothesized
that CXCR7 might be involved in adhesion of cells to
peritubular capillaries and lymphatic vessels.
In summary, CXCR7 on endothelial cells might modulate
the recruitment of inflammatory cells and the activation of
endothelial cells in renal allografts. These hypotheses generated
with the help of our new morphological findings should now
be tested in functional studies. CXCR7-deficient mice die
shortly after birth due to heart malformations, which makes
allograft models in these mice impossible.20 Therefore, CXCR7
blocking agents will have to be used to further define the
biological function of CXCR7 in allograft injury.
MATERIALS AND METHODS
Study population for the localization of CXCR7 by
immunohistochemistry
Renal allograft biopsies were formalin-fixed and paraffin-embedded
following routine protocols (the morphological parameters are
summarized in Table 2). Archival sections were used in this study.
Included were a total of 64 indication allograft biopsies with acute
interstitial rejection (Banff I, n¼ 22), acute vascular rejection (Banff
II, n¼ 11), allograft biopsies with signs of chronic injury (n¼ 6),
C4d-positive biopsies with either no signs of cellular rejection
(n¼ 8) or additional signs of cellular rejection (n¼ 5). Biopsies
taken before allograft implantation served as controls (n¼ 12). An
additional series of 24 protocol biopsies were included. These
biopsies included 12 without significant lesions, 7 with acute forms
of rejection (borderline, n¼ 4; Banff I, n¼ 2; Banff 2, n¼ II), and 5
with chronic lesions with interstitial fibrosis and tubular atrophy.
CXCR7 was localized in all specimens by immunohistochemistry.
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Real-time RT-PCR
To quantify the mRNA expression of CXCR7, CXCL11, and
CXCL12, we used real-time RT-PCR as described.40 The biopsy
samples used for the mRNA analysis were from a different cohort
than the morphological study. Clinical data are summarized in
Table 1. The renal biopsies were obtained from a multicenter renal
biopsy bank (the European Renal cDNA Bank–Kroener-Fresenius
biopsy bank). Informed consent was obtained before renal biopsies
were performed. Microdissected tubulointerstitial compartments
were from a total of 53 biopsies with borderline lesions (n¼ 12),
acute rejection (n¼ 23, Banff 97 I, 10; Banff 97 II, 13), signs of
chronic injury (interstitial fibrosis and tubular atrophy, n¼ 10), and
biopsies taken before implantation from living donors as controls
(n¼ 8).
Reverse-transcription and real-time RT-PCR was performed as
reported earlier.41 Pre-developed TaqMan reagents were used for the
human target genes CXCR7, CXCL11, and CXCL12 (all from
Applied Biosystems, Darmstadt, Germany), and two endogenous
control genes (18S rRNA and GAPDH; Applied Biosystems). The
expression of target genes was normalized by both reference genes,
18S rRNA and hGAPDH, which resulted in comparable results. Data
shown are normalized to GAPDH. The mRNA expression was
analyzed by standard curve quantification. All measurements were
performed in duplicates. Controls consisting of double distilled
water were negative in all runs.
Immunohistochemistry
Immunohistochemistry was performed as previously described.2
In brief, dewaxed and rehydrated tissue sections were incubated
in 3% hydrogen peroxide (to block endogenous peroxidases).
The Avidin/Biotin blocking Kit (Vector, Burlingame, CA) was used
to block endogenous biotin. Antigen retrieval was performed in
an autoclave oven in Antigen retrieval solution (Vector). The
primary antibodies were applied for 1 h. Incubation with bio-
tinylated secondary antibodies (Vector) for 30min was followed
by the ABC reagent (Vector). 3030-Diaminobenzidine (Sigma,
Taufkirchen, Germany) with metal enhancement (resulting in a
black color product) was used as a detection system. As the primary
antibody a monoclonal mouse anti-human CXCR7 (provided by
ChemoCentryx, Mountain View, CA, USA) was used. This antibody
has been previously described in detail.8,42
Establishment of the antibody
Human tonsils and allograft nephrectomies were used to establish
the staining protocol. A heat-based antigen retrieval (using an
autoclave oven) resulted in a very reliable staining pattern
(Figure 7). The isotype IgG controls did not show black color
product (Figure 7a). CXCR7 was predominantly expressed on
endothelial cells of small vessels and capillaries, and larger veins
showed CXCR7-positive endothelial cells (Figure 7). High endothe-
lial venules and leukocytes were CXCR7 negative. The basal
epithelial layer was found to be CXCR7 positive.
Immunofluorescence
Multicolor immunofluorescence was performed for CXCR7 and
podoplanin (a marker of lymphatic endothelium) on all indication
biopsies. The monoclonal antibody D2-40 was used to detect
podoplanin and was visualized with a Cy3-labeled secondary
antibody (Jackson ImmunoResearch Laboratories, West Grove,
PA). CXCR7 was visualized by a biotinylated secondary and
labeled with FITC bound to streptavidin (Vector). After the first
antigen was labeled, another microwave treatment was performed
to omit cross-reaction of secondary antibodies. Negative controls
consisted of isotype immunoglobulins for both primary antibodies.
Statistics and quantification of results
The number of CXCR7-positive vessels, podoplanin-positive
lymphatics, and double-positive lymphatics were counted per high
power field (original magnification  400) by two observers masked
to the diagnosis. The mean of the two quantifications is shown.
For the protocol biopsies, 10 digital pictures (original magnifica-
tion  250) were taken, and the number of positive vessels was
evaluated by an observer masked to the diagnosis. The nonpara-
metric Kruskal–Wallis test was used to compare the mean number of
positive vessels. A value of Po0.05 was considered to be significant.
Error bars show standard error of the mean (s.e.m).
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